Key opinions leaders in the field of haematopoetic stem cell transplantation (HSCT) will address the role of Cyclophosphamide, an anti-cancer chemotherapy drug, during the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that will welcome more than 4,500 delegates in the host city of Valencia, Spain from the 3rd to the 6th of April 2016.

rss feed